Date: June 19, 2023
Time: 12:30-1:30pm ET
Overview:
The treatment of multiple myeloma is continually evolving with the introduction of novel therapies and new combination regimens. These advances present ongoing opportunities to tailor treatment approaches for patients with multiple myeloma based on disease-related and patient-related factors.
This activity will update oncology health care professionals on the most recent data from key abstracts focusing on multiple myeloma that were presented at the June 2023 annual meetings of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, and the European Hematology Association (EHA) Congress held in Frankfurt, Germany. By placing the data in clinical context, oncology practitioners can assess and apply these findings to their clinical practice and ultimately improve care for their patients with multiple myeloma.
Target audience:
This educational activity is directed toward hematologist/medical oncologists, NPs and nurses interested in the treatment of multiple myeloma.
Learning objectives:
- Describe the novel targets and mechanisms of actions for emerging therapeutic agents under evaluation for MM management
- Evaluate recent trial data from studies that assessed emerging therapies among patients with MM
- Devise strategies to effectively monitor and care for patients with treatment-related toxicities in R/R MM care settings
- Investigate the clinical implications of MM clinical trials in the context of rapidly changing treatment paradigms in the field
Benefits of Attending:
- Stay up-to-date with the latest data on the treatment of multiple myeloma hot off the press from the 2023 ASCO and EHA meetings
- Gain insights into how new evidence can be implemented into your practice right away
- Ask our expert panel your most burning questions about new and future directions for the treatment of multiple myeloma
Hot Topics:
- Is CAR T-cell therapy ready for use in early relapsed settings?
- How do bispecific T-cell engagers fit into new treatment paradigms for relapsed/refractory multiple myeloma?
- What is the latest data on novel combination regimens?
- Are there any new insights into optimal sequencing strategies?
Welcome and Pre-session Survey | 12:00 PM | Irene Ghobrial |
Data Presentations: Abstracts 1 and 2 | 12:05 PM | Irene Ghobrial |
Data Presentations: Abstracts 3 and 4 | 12:20 PM | Surbhi Sidana |
Data Presentations: Abstracts 5 and 6 | 12:35 PM | Nisha Joseph |
Data Presentations: Abstracts 7 and 8 | 12:50 PM | Krina Patel |
Panel Discussion: Applying the Latest Data and Ongoing Trials to the Care of Your Patients | 1:05 PM | Moderator: Irene Ghobrial |
Audience Q&A | 1:25 PM | Moderator: Irene Ghobrial |
Concluding Remarks and Adjourn | 1:30 PM | Irene Ghobrial |
Irene M. Ghobrial, MD
Lavine Family Chair of Preventative Cancer Therapy
Professor of Medicine
Director of the Center for Prevention of Progression
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.